FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591227806> ?p ?o ?g. }

• W2591227806 endingPage "62" @default.
• W2591227806 startingPage "42" @default.
• W2591227806 abstract "Next-Generation Sequencing & Molecular Diagnostics Clinical relevance of miRNAs in cancerHong Kiat NgChee-Seng KuDavid N CooperRichie SoongHong Kiat NgHong Kiat Ng is currently a PhD candidate studying at the Cancer Science Institute of Singapore, National University of Singapore. His research interests focus on applying high-throughput technologies to study epigenetic markers for identification of cancer biomarkers, as well as their role in tumorgenesis.Search for more papers by this authorChee-Seng KuKu Chee-Seng completed his PhD at the National University of Singapore in 2011/2012. He then worked as a Research Associate at the Cancer Science Institute of Singapore. His research interests focus on applying high-throughput microarray and sequencing technologies for studies on human genetic variation, disease genetics (Mendelian and complex diseases) and for diagnostics application. Currently, he is a Foreign Adjunct Faculty at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet (Sweden) and a Honorary Adjunct Research Fellow in the Saw Swee Hock School of Public Health, National University of Singapore. He is also serving on the editorial board of several international journals, including Human Genetics, Journal of Medical Genetics and Human Genomics.Search for more papers by this authorDavid N CooperDavid N Cooper is Professor of Human Molecular Genetics at Cardiff University, UK. His research interests are largely focused upon elucidating the mechanisms of mutagenesis underlying human genetic disease. He has published over 350 papers in the field of human molecular genetics and has coauthored/coedited a number of books on mutation in the context of inherited disease or molecular evolution. He curates the Human Gene Mutation Database (www.hgmd.org) and is European Editor of Human Genetics.Search for more papers by this authorRichie SoongSearch for more papers by this authorPublished Online:13 Feb 2013https://doi.org/10.2217/ebo.12.131AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit View chapterAbstract: High-throughput genomic technologies have potentiated the large-scale measurement of coding and noncoding transcript expression for the characterization of the molecular basis of disease. In addition, mRNA expression signatures have been found to be very useful in clinical applications, such as in the classification of cancer types and subtypes. Thus, the US FDA has given their approval to several mRNA expression tests for breast cancer (e.g., MammaPrint, PAM50, MapQuant Dx™ and OncotypeDX®) to be used both in prognosis assessment and for the prediction of therapeutic response. However, more recently, the expression signatures of miRNAs have also emerged as useful biomarkers for these applications. Indeed, miRNAs have several inherent advantages over mRNAs with respect to expression profiling. Finally, dysregulation of miRNA expression as a hallmark of cancer has led to the development of small molecules, such as miRNA antagonists and miRNA sponges, that can be used in a therapeutic context either to inhibit overexpressed oncogenic miRNAs, or to restore the normal expression of tumor-suppressive miRNAs using miRNA mimics. Taken together, miRNAs appear to have a very promising future both as clinical markers and therapeutic tools in cancer. References1 Lizardi PM , Forloni M , Wajapeyee N . Genome-wide approaches for cancer gene discovery . Trends Biotechnol. 29 (11) , 558 – 568 (2011) . Crossref, Medline, CAS, Google Scholar2 Kasaian K , Jones SJ . A new frontier in personalized cancer therapy: mapping molecular changes . Future Oncol. 7 (7) , 873 – 894 (2011) . Link, CAS, Google Scholar3 Glas AM , Floore A , Delahaye LJ et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test . BMC Genomics 7 , 278 (2006) . Crossref, Medline, Google Scholar4 Korde LA , Lusa L , McShane L et al. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer . Breast Cancer Res. Treat 119 (3) , 685 – 699 (2010) . Crossref, Medline, CAS, Google Scholar5 Loi S , Haibe-Kains B , Desmedt C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade . J. Clin. Oncol. 25 (10) , 1239 – 1246 (2007) . Crossref, Medline, CAS, Google Scholar6 Paik S , Shak S , Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer . N. Engl. J. Med. 351 (27) , 2817 – 2826 (2004) . Crossref, Medline, CAS, Google Scholar7 Webber EM , Lin JS , Whitlock EP . Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction . PLoS Curr. 2 , pii:RRN1177 (2010) . Crossref, Google Scholar8 Kratz JR , He J , Van Den Eeden SK et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies . Lancet 379 (9818) , 823 – 832 (2012) . Crossref, Medline, Google Scholar9 Huang L , Zheng M , Zhou QM et al. Identification of a 7-gene signature that predicts relapse and survival for early stage patients with cervical carcinoma . Med. Oncol. doi:10.1007/s12032-012-0166-3 (2012) (Epub ahead of print) . Crossref, Google Scholar10 Iorio MV , Croce CM . MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review . EMBO Mol. Med. 4 (3) , 143 – 159 (2012) . Crossref, Medline, CAS, Google Scholar11 Bartel DP . MicroRNAs: genomics, biogenesis, mechanism, and function . Cell 116 (2) , 281 – 297 (2004) . Crossref, Medline, CAS, Google Scholar12 Lee Y , Kim M , Han J et al. MicroRNA genes are transcribed by RNA polymerase II . EMBO J. 23 (20) , 4051 – 4060 (2004) . Crossref, Medline, CAS, Google Scholar13 Bartel DP . MicroRNAs: target recognition and regulatory functions . Cell 136 (2) , 215 – 233 (2009) . Crossref, Medline, CAS, Google Scholar14 Lewis BP , Burge CB , Bartel DP . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets . Cell 120 (1) , 15 – 20 (2005) . Crossref, Medline, CAS, Google Scholar15 Kozomara A , Griffiths-Jones S . miRBase: integrating microRNA annotation and deep-sequencing data . Nucleic Acids Res. 39 (Suppl. 1) , D152 – D157 (2011) . Crossref, Medline, CAS, Google Scholar16 Sayed D , Abdellatif M . MicroRNAs in development and disease . Physiol. Rev. 91 (3) , 827 – 887 (2011) . Crossref, Medline, CAS, Google Scholar17 Farazi TA , Spitzer JI , Morozov P , Tuschl T . miRNAs in human cancer . J. Pathol. 223 (2) , 102 – 115 (2011) . Crossref, Medline, CAS, Google Scholar18 Lu J , Getz G , Miska EA et al. MicroRNA expression profiles classify human cancers . Nature 435 (7043) , 834 – 838 (2005) . Crossref, Medline, CAS, Google Scholar19 Volinia S , Calin GA , Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets . Proc. Natl Acad. Sci. USA 103 (7) , 2257 – 2261 (2006) . Crossref, Medline, CAS, Google Scholar20 Calin GA , Sevignani C , Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers . Proc. Natl Acad. Sci. USA 101 (9) , 2999 – 3004 (2004) . Crossref, Medline, CAS, Google Scholar21 Landau DA , Slack FJ . MicroRNAs in mutagenesis, genomic instability, and DNA repair . Semin. Oncol. 38 (6) , 743 – 751 (2011) . Crossref, Medline, CAS, Google Scholar22 Iorio MV , Visone R , Di Leva G et al. MicroRNA signatures in human ovarian cancer . Cancer Res. 67 (18) , 8699 – 8707 (2007) . Crossref, Medline, CAS, Google Scholar23 Moskwa P , Buffa FM , Pan Y et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors . Mol. Cell 41 (2) , 210 – 220 (2011) . Crossref, Medline, CAS, Google Scholar24 Zheng B , Liang L , Wang C et al. MicroRNA-148a Suppresses Tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer . Clin. Cancer Res. 17 (24) , 7574 – 7583 (2011) . Crossref, Medline, CAS, Google Scholar25 Brueckner B , Stresemann C , Kuner R et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function . Cancer Res. 67 (4) , 1419 – 1423 (2007) . Crossref, Medline, CAS, Google Scholar26 Gong J , Tong Y , Zhang HM et al. Genome-wide identification of .s in microRNA genes and the effects on microRNA target binding and biogenesis . Hum. Mutat. 33 (1) , 254 – 263 (2012) . Crossref, Medline, CAS, Google Scholar27 Mencia A , Modamio-Hoybjor S , Redshaw N et al. Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss . Nat. Genet. 41 (5) , 609 – 613 (2009) . Crossref, Medline, CAS, Google Scholar28 Sun G , Yan J , Noltner K et al. SNPs in human miRNA genes affect biogenesis and function . RNA 15 (9) , 1640 – 1651 (2009) . Crossref, Medline, CAS, Google Scholar29 Lytle JR , Yario TA , Steitz JA . Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5´ UTR as in the 3´ UTR . Proc. Natl Acad. Sci. USA 104 (23) , 9667 – 9672 (2007) . Crossref, Medline, CAS, Google Scholar30 Schnall-Levin M , Rissland OS , Johnston WK , Perrimon N , Bartel DP , Berger B . Unusually effective microRNA targeting within repeat-rich coding regions of mammalian mRNAs . Genome Res. 21 (9) , 1395 – 1403 (2011) . Crossref, Medline, CAS, Google Scholar31 Moretti F , Thermann R , Hentze MW . Mechanism of translational regulation by miR-2 from sites in the 5´ untranslated region or the open reading frame . RNA 16 (12) , 2493 – 2502 (2010) . Crossref, Medline, CAS, Google Scholar32 Vasudevan S , Tong Y , Steitz JA . Switching from repression to activation: microRNAs can up-regulate translation . Science 318 (5858) , 1931 – 1934 (2007) . Crossref, Medline, CAS, Google Scholar33 Place RF , Li LC , Pookot D , Noonan EJ , Dahiya R . MicroRNA-373 induces expression of genes with complementary promoter sequences . Proc. Natl Acad. Sci. USA 105 (5) , 1608 – 1613 (2008) . Crossref, Medline, CAS, Google Scholar34 Cheng Q , Chang JT , Geradts J et al. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer . Breast Cancer Res. 14 (2) , R62 (2012) . Crossref, Medline, CAS, Google Scholar35 Irgon J , Huang CC , Zhang Y , Talantov D , Bhanot G , Szalma S . Robust multi-tissue gene panel for cancer detection . BMC Cancer 10 , 319 (2010) . Crossref, Medline, CAS, Google Scholar36 Galamb O , Sipos F , Solymosi N et al. Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results . Cancer Epidemiol. Biomarkers Prev. 17 (10) , 2835 – 2845 (2008) . Crossref, Medline, CAS, Google Scholar37 Zhao X , Rodland EA , Sorlie T et al. Combining gene signatures improves prediction of breast cancer survival . PLoS ONE 6 (3) , e17845 (2011) . Crossref, Medline, CAS, Google Scholar38 Lee RC , Feinbaum RL , Ambros V . The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 . Cell 75 (5) , 843 – 854 (1993) . Crossref, Medline, CAS, Google Scholar39 Calin GA , Dumitru CD , Shimizu M et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia . Proc. Natl Acad. Sci. USA 99 (24) , 15524 – 15529 (2002) . Crossref, Medline, CAS, Google Scholar40 Schulte JH , Marschall T , Martin M et al. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma . Nucleic Acids Res. 38 (17) , 5919 – 5928 (2010) . Crossref, Medline, CAS, Google Scholar41 Liu A , Tetzlaff MT , Vanbelle P et al. MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues . Int. J. Clin. Exp. Pathol. 2 (6) , 519 – 527 (2009) . Medline, CAS, Google Scholar42 Donahue TR , Tran LM , Hill R et al. Integrative survival-based molecular profiling of human pancreatic cancer . Clin. Cancer Res. 18 (5) , 1352 – 1363 (2012) . Crossref, Medline, CAS, Google Scholar43 Lanza G , Ferracin M , Gafa R et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer . Mol. Cancer 6 , 54 (2007) . Crossref, Medline, Google Scholar44 Sieuwerts AM , Mostert B , Bolt-de Vries J et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients . Clin. Cancer Res. 17 (11) , 3600 – 3618 (2011) . Crossref, Medline, CAS, Google Scholar45 Rosenfeld N , Aharonov R , Meiri E et al. MicroRNAs accurately identify cancer tissue origin . Nat. Biotechnol. 26 (4) , 462 – 469 (2008) . Crossref, Medline, CAS, Google Scholar46 Massard C , Loriot Y , Fizazi K . Carcinomas of an unknown primary origin – diagnosis and treatment . Nat. Rev. Clin. Oncol. 8 (12) , 701 – 710 (2011) . Crossref, Medline, CAS, Google Scholar47 Liu R , Zhang C , Hu Z et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis . Eur. J. Cancer 47 (5) , 784 – 791 (2011) . Crossref, Medline, CAS, Google Scholar48 Chen X , Ba Y , Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases . Cell Res. 18 (10) , 997 – 1006 (2008) . Crossref, Medline, CAS, Google Scholar49 Liu CJ , Lin SC , Yang CC , Cheng HW , Chang KW . Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma . Head Neck 34 (2) , 219 – 224 (2012) . Crossref, Medline, Google Scholar50 Yu L , Todd NW , Xing L et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers . Int. J. Cancer 127 (12) , 2870 – 2878 (2010) . Crossref, Medline, CAS, Google Scholar51 Bryant RJ , Pawlowski T , Catto JW et al. Changes in circulating microRNA levels associated with prostate cancer . Brit. J. Cancer 106 (4) , 768 – 774 (2012) . Crossref, Medline, CAS, Google Scholar52 Wu CW , Ng SS , Dong YJ et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps . Gut 61 (5) , 739 – 745 (2011) . Medline, Google Scholar53 Oberg AL , French AJ , Sarver AL et al. miRNA expression in colon polyps provides evidence for a multihit model of colon cancer . PLoS ONE 6 (6) , e20465 (2011) . Crossref, Medline, CAS, Google Scholar54 Li B , Hu Y , Ye F , Li Y , Lv W , Xie X . Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection . Int. J. Gynecol. Cancer 20 (4) , 597 – 604 (2010) . Crossref, Medline, Google Scholar55 Schrauder MG , Strick R , Schulz-Wendtland R et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection . PLoS ONE 7 (1) , e29770 (2012) . Crossref, Medline, CAS, Google Scholar56 Borel F , Konstantinova P , Jansen PL . Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma . J. Hepatol. 56 (6) , 1371 – 1383 (2012) . Crossref, Medline, CAS, Google Scholar57 Boeri M , Verri C , Conte D et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer . Proc. Natl Acad. Sci. USA 108 (9) , 3713 – 3718 (2011) . Crossref, Medline, CAS, Google Scholar58 Bianchi F , Nicassio F , Marzi M et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer . EMBO Mol. Med. 3 (8) , 495 – 503 (2011) . Crossref, Medline, CAS, Google Scholar59 Song MY , Pan KF , Su HJ et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer . PLoS ONE 7 (3) , e33608 (2012) . Crossref, Medline, CAS, Google Scholar60 Veronesi G , Bellomi M , Mulshine JL et al. Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules . Lung Cancer 61 (3) , 340 – 349 (2008) . Crossref, Medline, Google Scholar61 Kakinuma R , Ohmatsu H , Kaneko M et al. Detection failures in spiral CT screening for lung cancer: analysis of CT findings . Radiology 212 (1) , 61 – 66 (1999) . Crossref, Medline, CAS, Google Scholar62 Brase JC , Johannes M , Schlomm T et al. Circulating miRNAs are correlated with tumor progression in prostate cancer . Int. J. Cancer 128 (3) , 608 – 616 (2011) . Crossref, Medline, CAS, Google Scholar63 Liu XG , Zhu WY , Huang YY et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer . Med. Oncol. 29 (2) , 618 – 626 (2011) . Medline, Google Scholar64 Tsujiura M , Ichikawa D , Komatsu S et al. Circulating microRNAs in plasma of patients with gastric cancers . Br. J. Cancer 102 (7) , 1174 – 1179 (2010) . Crossref, Medline, CAS, Google Scholar65 Zhang X , Yan Z , Zhang J et al. Combination of hsa-miR-375 and hsa-miR-142–5p as a predictor for recurrence risk in gastric cancer patients following surgical resection . Ann. Oncol. 22 (10) , 2257 – 2266 (2011) . Crossref, Medline, CAS, Google Scholar66 Lu Y , Govindan R , Wang L et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer . Carcinogenesis 33 (5) , 1046 – 1054 (2012) . Crossref, Medline, CAS, Google Scholar67 Gallardo E , Navarro A , Vinolas N et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer . Carcinogenesis 30 (11) , 1903 – 1909 (2009) . Crossref, Medline, CAS, Google Scholar68 Ueda T , Volinia S , Okumura H et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis . Lancet Oncol. 11 (2) , 136 – 146 (2010) . Crossref, Medline, CAS, Google Scholar69 Blenkiron C , Goldstein LD , Thorne NP et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype . Genome Biol. 8 (10) , R214 (2007) . Crossref, Medline, Google Scholar70 Garzon R , Volinia S , Liu CG et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia . Blood 111 (6) , 3183 – 3189 (2008) . Crossref, Medline, CAS, Google Scholar71 Li X , Zhang Y , Ding J , Wu K , Fan D . Survival prediction of gastric cancer by a seven-microRNA signature . Gut 59 (5) , 579 – 585 (2010) . Crossref, Medline, CAS, Google Scholar72 Sempere LF , Christensen M , Silahtaroglu A et al. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer . Cancer Res. 67 (24) , 11612 – 11620 (2007) . Crossref, Medline, CAS, Google Scholar73 Lowery AJ , Miller N , Devaney A et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer . Breast Cancer Res. 11 (3) , R27 (2009) . Crossref, Medline, Google Scholar74 Fabbri M , Bottoni A , Shimizu M et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia . JAMA 305 (1) , 59 – 67 (2011) . Crossref, Medline, CAS, Google Scholar75 Li D , Liu X , Lin L et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma . J. Biol. Chem. 286 (42) , 36677 – 36685 (2011) . Crossref, Medline, CAS, Google Scholar76 Volinia S , Galasso M , Sana ME et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA . Proc. Natl Acad. Sci. USA 109 (8) , 3024 – 3029 (2012) . Crossref, Medline, CAS, Google Scholar77 Jamieson NB , Morran DC , Morton JP et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma . Clin. Cancer Res. 18 (2) , 534 – 545 (2012) . Crossref, Medline, CAS, Google Scholar78 Yamamoto Y , Yoshioka Y , Minoura K et al. An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells . Mol. Cancer 10 , 135 (2011) . Crossref, Medline, CAS, Google Scholar79 Ji J , Shi J , Budhu A et al. MicroRNA expression, survival, and response to interferon in liver cancer . N. Engl. J. Med. 361 (15) , 1437 – 1447 (2009) . Crossref, Medline, CAS, Google Scholar80 Tomimaru Y , Eguchi H , Nagano H et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells . Br. J. Cancer 103 (10) , 1617 – 1626 (2010) . Crossref, Medline, CAS, Google Scholar81 Hwang JH , Voortman J , Giovannetti E et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer . PLoS ONE 5 (5) , e10630 (2010) . Crossref, Medline, Google Scholar82 Giovannetti E , Funel N , Peters GJ et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity . Cancer Res. 70 (11) , 4528 – 4538 (2010) . Crossref, Medline, CAS, Google Scholar83 Boni V , Zarate R , Villa JC et al. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan . Pharmacogenomics J. 11 (6) , 429 – 436 (2011) . Crossref, Medline, CAS, Google Scholar84 Liang D , Meyer L , Chang DW et al. Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response . Cancer Res. 70 (23) , 9765 – 9776 (2010) . Crossref, Medline, CAS, Google Scholar85 Esquela-Kerscher A , Slack FJ . Oncomirs – microRNAs with a role in cancer . Nature Rev. Cancer 6 (4) , 259 – 269 (2006) . Crossref, Medline, CAS, Google Scholar86 Lee YS , Dutta A . MicroRNAs in cancer . Annu. Rev. Pathol. 4 , 199 – 227 (2009) . Crossref, Medline, CAS, Google Scholar87 Krutzfeldt J , Rajewsky N , Braich R et al. Silencing of microRNAs in vivo with ‘antagomirs’ . Nature 438 (7068) , 685 – 689 (2005) . Crossref, Medline, Google Scholar88 Meister G , Landthaler M , Dorsett Y , Tuschl T . Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing . RNA 10 (3) , 544 – 550 (2004) . Crossref, Medline, CAS, Google Scholar89 Orom UA , Kauppinen S , Lund AH . LNA-modified oligonucleotides mediate specific inhibition of microRNA function . Gene 372 , 137 – 141 (2006) . Crossref, Medline, CAS, Google Scholar90 Ebert MS , Neilson JR , Sharp PA . MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells . Nat. Methods 4 (9) , 721 – 726 (2007) . Crossref, Medline, CAS, Google Scholar91 Poliseno L , Salmena L , Zhang J , Carver B , Haveman WJ , Pandolfi PP . A coding-independent function of gene and pseudogene mRNAs regulates tumour biology . Nature 465 (7301) , 1033 – 1038 (2010) . Crossref, Medline, CAS, Google Scholar92 Elmen J , Lindow M , Schutz S et al. LNA-mediated microRNA silencing in non-human primates . Nature 452 (7189) , 896 – 899 (2008) . Crossref, Medline, CAS, Google Scholar93 Lanford RE , Hildebrandt-Eriksen ES , Petri A et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection . Science 327 (5962) , 198 – 201 (2010) . Crossref, Medline, CAS, Google Scholar94 Ma L , Reinhardt F , Pan E et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model . Nat. Biotechnol. 28 (4) , 341 – 347 (2010) . Crossref, Medline, CAS, Google Scholar95 Huynh C , Segura MF , Gaziel-Sovran A et al. Efficient in vivo microRNA targeting of liver metastasis . Oncogene 30 (12) , 1481 – 1488 (2011) . Crossref, Medline, CAS, Google Scholar96 Elyakim E , Sitbon E , Faerman A et al. HSA-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy . Cancer Res. 70 (20) , 8077 – 8087 (2010) . Crossref, Medline, CAS, Google Scholar97 Trang P , Wiggins JF , Daige CL et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice . Mol. Ther. 19 (6) , 1116 – 1122 (2011) . Crossref, Medline, CAS, Google Scholar98 Pramanik D , Campbell NR , Karikari C et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice . Mol. Cancer Ther. 10 (8) , 1470 – 1480 (2011) . Crossref, Medline, CAS, Google Scholar99 Takeshita F , Patrawala L , Osaki M et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes . Mol. Ther. 18 (1) , 181 – 187 (2010) . Crossref, Medline, CAS, Google Scholar100 Kota J , Chivukula RR , O’Donnell KA et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model . Cell 137 (6) , 1005 – 1017 (2009) . Crossref, Medline, CAS, Google Scholar101 Horwich MD , Zamore PD . Design and delivery of antisense oligonucleotides to block microRNA function in cultured Drosophila and human cells . Nat. Protoc. 3 (10) , 1537 – 1549 (2008) . Crossref, Medline, CAS, Google Scholar102 Zimmermann TS , Lee AC , Akinc A et al. RNAi-mediated gene silencing in non-human primates . Nature 441 (7089) , 111 – 114 (2006) . Crossref, Medline, CAS, Google Scholar103 Xu B , Wang N , Wang X et al. MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer . Prostate 72 (11) , 1171 – 1178 (2011) . Medline, Google Scholar104 Xiao B , Zhu ED , Li N et al. Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis . Oncol. Rep. 27 (2) , 559 – 566 (2012) . Medline, CAS, Google Scholar105 Garcia AI , Buisson M , Bertrand P et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers . EMBO Mol. Med. 3 (5) , 279 – 290 (2011) . Crossref, Medline, CAS, Google Scholar106 Liu C , Kelnar K , Liu B et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44 . Nat. Med. 17 (2) , 211 – 215 (2011) . Crossref, Medline, CAS, Google Scholar107 Liao J , Yu L , Mei Y et al. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer . Mol. Cancer 9 , 198 (2010) . Crossref, Medline, Google Scholar108 Gupta RA , Shah N , Wang KC et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis . Nature 464 (7291) , 1071 – 1076 (2010) . Crossref, Medline, CAS, Google Scholar109 Ozsolak F , Platt AR , Jones DR et al. Direct RNA sequencing . Nature 461 (7265) , 814 – 818 (2009) . Crossref, Medline, CAS, Google Scholar110 Kasinski AL , Slack FJ . Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy . Nat. Rev. Cancer 11 (12) , 849 – 864 (2011) . Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Next-Generation Sequencing & Molecular DiagnosticsMetrics Downloaded 15 times History Published online 13 February 2013 Published in print February 2013 Information© Future Medicine Ltd© Future Medicine LtdPDF download" @default.
• W2591227806 created "2017-03-03" @default.
• W2591227806 creator A5007850609 @default.
• W2591227806 creator A5042443600 @default.
• W2591227806 creator A5051144539 @default.
• W2591227806 creator A5069620179 @default.
• W2591227806 date "2013-02-01" @default.
• W2591227806 modified "2023-10-03" @default.
• W2591227806 title "Clinical relevance of miRNAs in cancer" @default.
• W2591227806 cites W144423133 @default.
• W2591227806 cites W1648301895 @default.
• W2591227806 cites W1965175512 @default.
• W2591227806 cites W1965714535 @default.
• W2591227806 cites W1966498224 @default.
• W2591227806 cites W1967703437 @default.
• W2591227806 cites W1970760326 @default.
• W2591227806 cites W1972551831 @default.
• W2591227806 cites W1972989638 @default.
• W2591227806 cites W1976871722 @default.
• W2591227806 cites W1979946545 @default.
• W2591227806 cites W1981052185 @default.
• W2591227806 cites W1996745846 @default.
• W2591227806 cites W1997639391 @default.
• W2591227806 cites W1997939286 @default.
• W2591227806 cites W1998635752 @default.
• W2591227806 cites W2001554877 @default.
• W2591227806 cites W2005895632 @default.
• W2591227806 cites W2007725123 @default.
• W2591227806 cites W2012254260 @default.
• W2591227806 cites W2012511861 @default.
• W2591227806 cites W2014180191 @default.
• W2591227806 cites W2017426710 @default.
• W2591227806 cites W2020326055 @default.
• W2591227806 cites W2022667041 @default.
• W2591227806 cites W2026866676 @default.
• W2591227806 cites W2028058995 @default.
• W2591227806 cites W2031341812 @default.
• W2591227806 cites W2032627213 @default.
• W2591227806 cites W2034729689 @default.
• W2591227806 cites W2035192299 @default.
• W2591227806 cites W2036727594 @default.
• W2591227806 cites W2042210471 @default.
• W2591227806 cites W2048577371 @default.
• W2591227806 cites W2060688862 @default.
• W2591227806 cites W2061452886 @default.
• W2591227806 cites W2061638986 @default.
• W2591227806 cites W2062533676 @default.
• W2591227806 cites W2063382533 @default.
• W2591227806 cites W2065543285 @default.
• W2591227806 cites W2066868410 @default.
• W2591227806 cites W2069009920 @default.
• W2591227806 cites W2070723183 @default.
• W2591227806 cites W2072537259 @default.
• W2591227806 cites W2076481272 @default.
• W2591227806 cites W2080029244 @default.
• W2591227806 cites W2081427413 @default.
• W2591227806 cites W2082887122 @default.
• W2591227806 cites W2083381199 @default.
• W2591227806 cites W2083457841 @default.
• W2591227806 cites W2084267800 @default.
• W2591227806 cites W2085256503 @default.
• W2591227806 cites W2089001345 @default.
• W2591227806 cites W2091798624 @default.
• W2591227806 cites W2093086801 @default.
• W2591227806 cites W2095151181 @default.
• W2591227806 cites W2095214257 @default.
• W2591227806 cites W2097233439 @default.
• W2591227806 cites W2097655831 @default.
• W2591227806 cites W2099507518 @default.
• W2591227806 cites W2100310273 @default.
• W2591227806 cites W2105493915 @default.
• W2591227806 cites W2105882193 @default.
• W2591227806 cites W2108104027 @default.
• W2591227806 cites W2108909227 @default.
• W2591227806 cites W2111471857 @default.
• W2591227806 cites W2113427027 @default.
• W2591227806 cites W2114786335 @default.
• W2591227806 cites W2116799486 @default.
• W2591227806 cites W2118723994 @default.
• W2591227806 cites W2119197194 @default.
• W2591227806 cites W2120920586 @default.
• W2591227806 cites W2122080063 @default.
• W2591227806 cites W2122906372 @default.
• W2591227806 cites W2123099342 @default.
• W2591227806 cites W2123962115 @default.
• W2591227806 cites W2124007301 @default.
• W2591227806 cites W2125382892 @default.
• W2591227806 cites W2130979840 @default.
• W2591227806 cites W2133096586 @default.
• W2591227806 cites W2135314242 @default.
• W2591227806 cites W2135810600 @default.
• W2591227806 cites W2136330412 @default.
• W2591227806 cites W2138485734 @default.
• W2591227806 cites W2138620103 @default.
• W2591227806 cites W2138664009 @default.
• W2591227806 cites W2138799354 @default.
• W2591227806 cites W2139966272 @default.
• W2591227806 cites W2142057493 @default.

• next